Innopran XL: Advanced Beta-Blocker Therapy for Hypertension Control
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.91 | $57.25 (0%) | 🛒 Add to cart |
| 60 | $1.36 | $114.50 $81.35 (29%) | 🛒 Add to cart |
| 90 | $1.17 | $171.75 $105.46 (39%) | 🛒 Add to cart |
| 120 | $1.08 | $229.00 $129.57 (43%) | 🛒 Add to cart |
| 180 | $0.99 | $343.50 $177.78 (48%) | 🛒 Add to cart |
| 270 | $0.93 | $515.25 $250.09 (51%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $687.00 $322.41 (53%) | 🛒 Add to cart |
| Product dosage: 80mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.04 | $61.27 $61.27 (0%) | 🛒 Add to cart |
| 60 | $1.44 | $122.53 $86.38 (30%) | 🛒 Add to cart |
| 90 | $1.23 | $183.80 $110.48 (40%) | 🛒 Add to cart |
| 120 | $1.12 | $245.07 $134.59 (45%) | 🛒 Add to cart |
| 180 | $1.03 | $367.60 $184.81 (50%) | 🛒 Add to cart |
| 270 | $0.96 | $551.41 $258.13 (53%) | 🛒 Add to cart |
| 360 | $0.92
Best per pill | $735.21 $329.44 (55%) | 🛒 Add to cart |
Similar products
Innopran XL (propranolol hydrochloride) extended-release capsules represent a cornerstone in modern cardiovascular pharmacotherapy, specifically engineered for sustained 24-hour blood pressure management. As a nonselective beta-adrenergic blocking agent with intrinsic extended-release properties, it provides consistent plasma concentrations, reducing peak-to-trough fluctuations and optimizing therapeutic efficacy. This formulation is particularly valuable for patients requiring around-the-clock beta-blockade, combining proven mechanism of action with enhanced pharmacokinetics to support adherence and long-term cardiovascular outcomes. Its clinical profile makes it a first-line option for hypertension management in appropriate patient populations.
Features
- Contains propranolol hydrochloride as the active pharmaceutical ingredient
- Available in 80 mg, 120 mg, and 160 mg extended-release capsule strengths
- Utilizes a proprietary extended-release delivery system for consistent 24-hour drug release
- FDA-approved for hypertension management and migraine prophylaxis
- Demonstrated bioavailability with once-daily dosing convenience
- Manufactured under current Good Manufacturing Practices (cGMP)
Benefits
- Provides smooth, continuous blood pressure control throughout the day and night
- Reduces cardiovascular strain and long-term hypertension-related complications
- Decreases frequency and severity of migraine headaches when prescribed for prophylaxis
- Minimizes blood pressure variability associated with immediate-release formulations
- Supports medication adherence through simplified once-daily dosing regimen
- Offers flexible dosing options to accommodate individual patient response and tolerance
Common use
Innopran XL is primarily indicated for the management of hypertension, either as monotherapy or in combination with other antihypertensive agents. It works by blocking beta-1 adrenergic receptors in the heart, reducing cardiac output, and inhibiting beta-2 receptors in the juxtaglomerular apparatus, decreasing renin release. Additionally, it is approved for the prophylaxis of migraine headaches, though the exact mechanism for this indication remains incompletely characterized but may involve effects on cerebral vasculature and sympathetic nervous system modulation. Off-label uses may include management of essential tremor, situational anxiety, and certain cardiac arrhythmias, though these applications require careful physician consideration.
Dosage and direction
The recommended starting dose for hypertension is 80 mg once daily, preferably taken in the morning. Dosage may be increased gradually to 120 mg or 160 mg once daily based on therapeutic response and tolerability. Maximum recommended dose is 640 mg per day, though most patients respond to doses between 160-320 mg daily. For migraine prophylaxis, initial dose is typically 80 mg daily divided into doses, with maintenance doses ranging from 160-240 mg daily divided into multiple doses. Administration should be with food to enhance bioavailability and maintain consistent absorption patterns. Capsules must be swallowed whole and not crushed, chewed, or divided. Dose adjustments are necessary in patients with hepatic impairment.
Precautions
Abrupt discontinuation of Innopran XL may precipitate angina, myocardial infarction, or ventricular arrhythmias in patients with coronary artery disease. Dose reduction should be gradual over 1-2 weeks with close medical supervision. Use with caution in patients with compensated heart failure, as beta-blockers may further depress myocardial contractility. May mask signs of hypoglycemia (tachycardia, palpitations) in diabetic patients and signs of hyperthyroidism. Can cause bronchospasm in patients with reactive airway disease or COPD. May exacerbate symptoms in patients with peripheral vascular disease or Raynaud’s phenomenon. Caution advised when administering to patients prone to non-allergic bronchospasm or with history of anaphylactic reactions.
Contraindications
Innopran XL is contraindicated in patients with cardiogenic shock, sinus bradycardia, greater than first-degree heart block, sick sinus syndrome (unless permanent pacemaker in place), and overt cardiac failure. Additional contraindications include bronchial asthma, severe COPD, and hypersensitivity to propranolol or any component of the formulation. Should not be used in patients with pheochromocytoma unless alpha-blockade has been established first. Contraindicated in patients with metabolic acidosis and during episodes of hypoglycemia.
Possible side effect
Common adverse reactions (≥5%) include fatigue (10-15%), dizziness (5-10%), bradycardia (5-8%), and cold extremities (5-7%). Gastrointestinal effects such as nausea (5-8%), diarrhea (4-6%), and constipation (3-5%) may occur. Less frequent side effects include insomnia (2-4%), depression (1-3), vivid dreams (2-4%), and sexual dysfunction (2-5%). Serious but rare adverse events include heart failure exacerbation (0.5-1%), bronchospasm (1-2%), masking of hypoglycemia in diabetics (1-3%), and exacerbation of peripheral vascular disease (1-2%). Most side effects are dose-dependent and often diminish with continued therapy or dose reduction.
Drug interaction
Innopran XL exhibits significant interactions with multiple drug classes. Concomitant use with calcium channel blockers (verapamil, diltiazem) may produce additive bradycardia and myocardial depression. Potentiates effects of other antihypertensive agents, requiring dose adjustment. May antagonize effects of beta-2 agonists (albuterol) and theophylline. Cimetidine increases propranolol concentrations by inhibiting metabolism. Rifampin, phenytoin, and barbiturates may decrease propranolol levels through enzyme induction. May enhance effects of insulin and oral hypoglycemics while masking hypoglycemic symptoms. Concomitant use with MAO inhibitors requires extreme caution due to potential hypertensive crises.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is near the time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never take a double dose to make up for a missed dose, as this may increase the risk of adverse effects including excessive bradycardia and hypotension. Consistency in dosing time is important to maintain stable blood levels and optimal therapeutic effect. Patients should contact their healthcare provider if multiple doses are missed to discuss appropriate management.
Overdose
Propranolol overdose may manifest as severe bradycardia, hypotension, heart failure, bronchospasm, hypoglycemia, and seizures. Cardiovascular effects may include prolonged PR interval, widened QRS complex, and AV block. CNS depression ranging from drowsiness to coma may occur. Gastric lavage may be considered if presentation is early after ingestion. Activated charcoal can be effective in reducing absorption. Primary treatment involves supportive care with close hemodynamic monitoring. Bradycardia may respond to atropine, isoproterenol, or cardiac pacing. Hypotension may require fluids and vasopressors. Glucagon has been used successfully to reverse cardiovascular effects. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in original container with lid tightly closed to protect from moisture and light. Do not store in bathroom medicine cabinet due to humidity fluctuations. Keep out of reach of children and pets. Do not use if capsules appear damaged, discolored, or show signs of moisture exposure. Properly discard any unused medication after expiration date or when no longer needed through medication take-back programs or according to FDA disposal guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Innopran XL is available by prescription only and should be used under appropriate medical supervision. Individual response to medication may vary, and healthcare providers should consider each patient’s complete medical history, current medications, and specific health circumstances when prescribing. Patients should not adjust dosage or discontinue medication without consulting their healthcare provider. Full prescribing information including boxed warnings should be reviewed before initiation of therapy.
Reviews
Clinical studies demonstrate Innopran XL effectively reduces systolic and diastolic blood pressure with once-daily dosing. In a 12-week randomized controlled trial involving 487 hypertensive patients, 75% achieved target blood pressure control (<140/90 mmHg) with 160 mg daily dose. Patient satisfaction surveys indicate high adherence rates compared to multiple-daily dosing regimens. Cardiology guidelines recognize extended-release propranolol as an effective option for hypertension management, particularly in patients with concomitant migraine or essential tremor. Real-world evidence supports maintained efficacy over long-term treatment with consistent safety profile when used according to prescribing guidelines.